Phase I Study of RO7566802 in Combination with Atezolizumab for Solid Tumors
Genentech is conducting a first-in-human Phase I trial to evaluate RO7566802 alone and with atezolizumab in advanced solid tumors.
Phase I
Oncology / Solid Tumors
Status
Active
Sponsor
Roche
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The Phase I trial of RO7566802 in combination with atezolizumab represents a significant development in oncology, potentially enhancing Genentech's competitive positioning in the market. Monitoring the trial's progress is crucial as successful outcomes could lead to new treatment options for advanced solid tumors.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include initial safety data and efficacy results from the dose escalation and expansion phases.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.